Photo from wikipedia
Niraparib showed promising signs of efficacy in the phase II GALAHAD trial of men with advanced prostate cancer whose tumors harbor mutations in the DNA damage-response pathway, especially among patients… Click to show full abstract
Niraparib showed promising signs of efficacy in the phase II GALAHAD trial of men with advanced prostate cancer whose tumors harbor mutations in the DNA damage-response pathway, especially among patients with gene defects in BRCA1 or BRCA2.
Keywords:
shrinks brca;
prostate tumors;
mutated prostate;
niraparib shrinks;
brca mutated
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!